Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-cell responses in macaques

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Lorin, Clarisse ^a   Vanloubbeeck, Yannick ^a   Baudart, Sébastien ^a   Ska, Michaël ^a   Bayat, Babak ^a   Brauers, Geoffroy ^a   Clarinval, Géraldine ^a   Donner, Marie Noëlle ^a   Marchand, Martine ^a   Koutsoukos, Marguerite ^a   Mettens, Pascal ^a   Cohen, Joe ^a   Voss, Gerald ^a  

^a GSK   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYTOKINE; F4 PROTEIN; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; NEF PROTEIN; RECOMBINANT CHIMPANZEE ADENOVIRUS TYPE 7 VECTOR; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; HYBRID PROTEIN; NEF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; P17 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS TYPE 1; VIRUS ANTIBODY; VIRUS VACCINE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; CLADISTICS; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; HETEROLOGOUS IMMUNITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; IMMUNOMODULATION; INTESTINE CELL; LIVER CELL; LYMPHOCYTE FUNCTION; MACACA; MEMORY T LYMPHOCYTE; MOUSE; MUCOSA CELL; NONHUMAN; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SPLEEN CELL; T LYMPHOCYTE; VIRUS CELL INTERACTION; VIRUS TYPING; ADENOVIRIDAE; ANIMAL; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE VECTOR; GENETICS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; PAN TROGLODYTES; STRUCTURAL GENE;

CHIMPANZEE ADENOVIRUS; HUMAN ADENOVIRUS; HUMAN ADENOVIRUS TYPE 7; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MUS; PAN; SIMIAN IMMUNODEFICIENCY VIRUS;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENES, POL; GENETIC VECTORS; HIV ANTIGENS; HIV CORE PROTEIN P24; HIV-1; INJECTIONS, INTRAMUSCULAR; MACACA; MICE; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PAN TROGLODYTES; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; VIRAL VACCINES;

EID: 84928776211     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122835     Document Type: Review

References (86)

1. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994; 68: 6103-6110. PMID: 8057491
2. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, Ganusov VV, et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med. 2009; 206: 1253-1272. doi: 10.1084/jem.20090365 PMID: 19487423
3. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, BorkowskyW, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994; 68: 4650-4655. PMID: 8207839
4. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011; 473: 523-527. doi: 10.1038/nature10003 PMID: 21562493
5. Hansen SG, Piatak M Jr., Ventura AB, Hughes CM, Gilbride RM, Ford JC, et al. Immune clearance of highly pathogenic SIV infection. Nature. 2013; 502: 100-104. doi: 10.1038/nature12519 PMID: 24025770
6. Jansen CA, Van Baarle D, Miedema F. HIV-specific CD4+ T cells and viremia: who's in control? Trends Immunol. 2006; 27: 119-124. PMID: 16458605
7. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003; 421: 852-856. PMID: 12594515
8. Sun JC, Williams MA, Bevan MJ. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol. 2004; 5: 927-933. PMID: 15300249
9. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006; 107: 4781-4789. PMID: 16467198
10. Boaz MJ, Waters A, Murad S, Easterbrook PJ, Vyakarnam A. Presence of HIV-1 Gag-specific IFN-γ+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. J Immunol. 2002; 169: 6376-6385. PMID: 12444145
11. Hersperger AR, Pereyra F, Nason M, Demers K, Sheth P, Shin LY, et al. Perforin expression directly ex vivo by HIV-specific CD8+ T-cells is a correlate of HIV elite control. PLoS Pathog. 2010; 6: e1000917. doi: 10.1371/journal.ppat.1000917 PMID: 20523897
12. Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol. 2007; 81: 8468-8476. PMID: 17553885
13. Potter SJ, Lacabaratz C, Lambotte O, Perez-Patrigeon S, Vingert B, Sinet M, et al. Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol. 2007; 81: 13904-13915. PMID: 17928341
14. McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity. 2010; 33: 542-554. doi: 10.1016/j.immuni.2010.09.011 PMID: 21029964
15. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol. 2010; 10: 11-23. doi: 10.1038/nri2674 PMID: 20010788
16. Barouch DH. Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS. 2010; 5: 386-390. doi: 10.1097/COH.0b013e32833cfe4c PMID: 20978378
17. Barouch DH, O'Brien KL, Simmons NL, King SL, Abbink P, Maxfield LF, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med. 2010; 16: 319-323. doi: 10.1038/nm.2089 PMID: 20173752
18. Kaufman DR, Liu J, Carville A, Mansfield KG, Havenga MJ, Goudsmit J, et al. Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination. J Immunol. 2008; 181: 4188-4198. PMID: 18768876
19. Li H, Liu J, Carville A, Mansfield KG, Lynch D, Barouch DH. Durable mucosal simian immunodeficiency virus-specific effector memory T lymphocyte responses elicited by recombinant adenovirus vectors in rhesus monkeys. J Virol. 2011; 85: 11007-11015. doi: 10.1128/JVI.05346-11 PMID: 21917969
20. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature. 2009; 457: 87-91. doi: 10.1038/nature07469 PMID: 18997770
21. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002; 415: 331-335. PMID: 11797011
22. Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell. 2013; 155: 531-539. doi: 10.1016/j.cell.2013.09.061 PMID: 24243013
23. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012; 482: 89-93. doi: 10.1038/nature10766 PMID: 22217938
24. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008; 372: 1881-1893. doi: 10.1016/S0140-6736(08)61591-3 PMID: 19012954
25. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011; 11: 507-515. doi: 10.1016/S1473-3099(11)70098-6 PMID: 21570355
26. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008; 372: 1894-1905. doi: 10.1016/S0140-6736(08)61592-5 PMID: 19012957
27. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med. 2013; 369: 2083-2092. doi: 10.1056/NEJMoa1310566 PMID: 24099601
28. Chen H, Xiang ZQ, Li Y, Kurupati RK, Jia B, Bian A, et al. Adenovirus-based vaccines: comparison of vectors from three species of Adenoviridae. J Virol. 2010; 84: 10522-10532. doi: 10.1128/JVI.00450-10 PMID: 20686035
29. Dudareva M, Andrews L, Gilbert SC, Bejon P, Marsh K, Mwacharo J, et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine. 2009; 27: 3501-3504. doi: 10.1016/j.vaccine.2009.03.080 PMID: 19464527
30. Farina SF, Gao GP, Xiang ZQ, Rux JJ, Burnett RM, Alvira MR, et al. Replication-defective vector based on a chimpanzee adenovirus. J Virol. 2001; 75: 11603-11613. PMID: 11689642
31. Zhi Y, Figueredo J, Kobinger GP, Hagan H, Calcedo R, Miller JR, et al. Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus. Hum Gene Ther. 2006; 17: 500-506. PMID: 16716107
32. Tatsis N, Lasaro MO, Lin SW, Haut LH, Xiang ZQ, Zhou D, et al. Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens. J Immunol. 2009; 182: 6587-6599. doi: 10.4049/jimmunol.0900317 PMID: 19414814
33. Tatsis N, Tesema L, Robinson ER, Giles-DavisW, McCoy K, Gao GP, et al. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther. 2006; 13: 421-429. PMID: 16319951
34. Santra S, Sun Y, Korioth-Schmitz B, Fitzgerald J, Charbonneau C, Santos G, et al. Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine. 2009; 27: 5837-5845. doi: 10.1016/j.vaccine.2009.07.050 PMID: 19660588
35. Reyes-Sandoval A, Fitzgerald JC, Grant R, Roy S, Xiang ZQ, Li Y, et al. Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J Virol. 2004; 78: 7392-7399. PMID: 15220412
36. Pinto AR, Fitzgerald JC, Giles-Davis W, Gao GP, Wilson JM, Ertl HC. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol. 2003; 171: 6774-6779. PMID: 14662882
37. Fitzgerald JC, Gao GP, Reyes-Sandoval A, Pavlakis GN, Xiang ZQ, Wlazlo AP, et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol. 2003; 170: 1416-1422. PMID: 12538702
38. Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, Nicosia A, et al. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun. 2010; 78: 145-153. doi: 10.1128/IAI.00740-09 PMID: 19858306
39. Quinn KM, Da Costa A, Yamamoto A, Berry D, Lindsay RW, Darrah PA, et al. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J Immunol. 2013; 190: 2720-2735. doi: 10.4049/jimmunol.1202861 PMID: 23390298
40. Ogwang C, Afolabi M, Kimani D, Jagne YJ, Sheehy SH, Bliss CM, et al. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS One. 2013; 8: e57726. doi: 10.1371/journal.pone.0057726 PMID: 23526949
41. Ewer KJ, O'Hara GA, Duncan CJ, Collins KA, Sheehy SH, Reyes-Sandoval A, et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun. 2013; 4: 2836. doi: 10.1038/ncomms3836 PMID: 24284865
42. Capone S, Reyes-Sandoval A, Naddeo M, Siani L, Ammendola V, Rollier CS, et al. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine. 2011; 29: 256-265.
43. Capone S, D'Alise AM, Ammendola V, Colloca S, Cortese R, Nicosia A, et al. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev Vaccines. 2013; 12: 379-393. doi: 10.1586/erv.13.15 PMID: 23560919
44. Van Braeckel E, Bourguignon P, Koutsoukos M, Clement F, Janssens M, Carletti I, et al. An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers. Clin Infect Dis. 2011; 52: 522-531. doi: 10.1093/cid/ciq160 PMID: 21208909
45. Harrer T, Plettenberg A, Arastéh K, Van Lunzen J, Fätkenheuer G, Jaeger H, et al. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: A randomised placebo-controlled study. Vaccine. 2013; 32: 2657-2665. doi: 10.1016/j.vaccine.2013.10.030 PMID: 24144472
46. Leroux-Roels G, Bourguignon P, Willekens J, Janssens M, Clement F, Didierlaurent A, et al. Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine. Clin Vaccine Immunol. 2014; 21: 302-311. doi: 10.1128/CVI.00617-13 PMID: 24391139
47. Vaccari M, Trindade CJ, Venzon D, Zanetti M, Franchini G. Vaccine-induced CD8+ central memory T cells in protection from simian AIDS. J Immunol. 2005; 175: 3502-3507. PMID: 16148092
48. Pitcher CJ, Hagen SI, Walker JM, Lum R, Mitchell BL, Maino VC, et al. Development and homeostasis of T cell memory in rhesus macaque. J Immunol. 2002; 168: 29-43. PMID: 11751943
49. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med. 2007; 13: 46-53. PMID: 17173051
50. Van Braeckel E, Leroux-Roels G. HIV vaccines: can CD4+ T cells be of help? Hum Vaccin Immunother. 2012; 8: 1795-1798. doi: 10.4161/hv.21760 PMID: 22906935
51. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines. 2007; 6: 723-739. PMID: 17931153
52. Garçon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems. Expert Rev Vaccines. 2011; 10: 471-486. doi: 10.1586/erv.11.29 PMID: 21506645
53. Roshorm Y, Cottingham MG, Potash MJ, Volsky DJ, Hanke T. T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens decrease chimeric EcoHIV/NDK challenge virus load. Eur J Immunol. 2012; 42: 3243-3255. doi: 10.1002/eji.201242624 PMID: 22930183
54. Cervasi B, Carnathan DG, Sheehan KM, Micci L, Paiardini M, Kurupati R, et al. Immunological and virological analyses of rhesus macaques immunized with chimpanzee adenoviruses expressing the simian immunodeficiency virus Gag/Tat fusion protein and challenged intrarectally with repeated low doses of SIVmac. J Virol. 2013; 87: 9420-9430. doi: 10.1128/JVI.01456-13 PMID: 23804645
55. Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, O'Hara GA, et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One. 2012; 7: e31208. doi: 10.1371/journal.pone.0031208 PMID: 22363582
56. Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med. 2012; 4: 115ra2. doi: 10.1126/scitranslmed.3002925 PMID: 22218691
57. Penaloza-Macmaster P, Provine NM, Ra J, Borducchi EN, McNally A, Simmons NL, et al. Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors. J Virol. 2013; 87: 1373-1384. doi: 10.1128/JVI.02058-12 PMID: 23152535
58. Patel V, Jalah R, Kulkarni V, Valentin A, Rosati M, Alicea C, et al. DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proc Natl Acad Sci U S A. 2013; 110: 2975-2980. doi: 10.1073/pnas.1215393110 PMID: 23359688
59. Kulkarni V, Valentin A, Rosati M, Alicea C, Singh AK, Jalah R, et al. Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques. PLoS One. 2014; 9: e86254. doi: 10.1371/journal.pone.0086254 PMID: 24465991
60. Pillai VK, Kannanganat S, Penaloza-Macmaster P, Chennareddi L, Robinson HL, Blackwell J, et al. Different patterns of expansion, contraction and memory differentiation of HIV-1 Gag-specific CD8 T cells elicited by adenovirus type 5 and modified vaccinia Ankara vaccines. Vaccine. 2011; 29: 5399-5406. doi: 10.1016/j.vaccine.2011.05.083 PMID: 21651938
61. Tatsis N, Fitzgerald JC, Reyes-Sandoval A, Harris-McCoy KC, Hensley SE, Zhou D, et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood. 2007; 110: 1916-1923. PMID: 17510320
62. Mooij P, Balla-Jhagjhoorsingh SS, Beenhakker N, van Haaften P, Baak I, Nieuwenhuis IG, et al. Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens. J Virol. 2009; 83: 5881-5889. doi: 10.1128/JVI.02345-08 PMID: 19321612
63. Kannanganat S, Kapogiannis BG, Ibegbu C, Chennareddi L, Goepfert P, Robinson HL, et al. Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J Virol. 2007; 81: 12071-12076. PMID: 17728221
64. Divekar AA, Zaiss DM, Lee FE, Liu D, Topham DJ, Sijts AJ, et al. Protein vaccines induce uncommitted IL-2-secreting human and mouse CD4 T cells, whereas infections induce more IFN-γ-secreting cells. J Immunol. 2006; 176: 1465-1473. PMID: 16424174
65. Younes SA, Yassine-Diab B, Dumont AR, Boulassel MR, Grossman Z, Routy JP, et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med. 2003; 198: 1909-1922. PMID: 14676302
66. Iyasere C, Tilton JC, Johnson AJ, Younes S, Yassine-Diab B, Sekaly RP, et al. Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J Virol. 2003; 77: 10900-10909. PMID: 14512540
67. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999; 401: 708-712. PMID: 10537110
68. Van Braeckel E, Desombere I, Clement F, Vandekerckhove L, Verhofstede C, Vogelaers D, et al. Polyfunctional CD4+ T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine. Vaccine. 2013; 31: 3739-3746. doi: 10.1016/j.vaccine.2013.05.021 PMID: 23707169
69. Sáez-Cirión A, Sinet M, Shin SY, Urrutia A, Versmisse P, Lacabaratz C, et al. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol. 2009; 182: 7828-7837. doi: 10.4049/jimmunol.0803928 PMID: 19494307
70. Stephenson KE, Li H, Walker BD, Michael NL, Barouch DH. Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys. J Virol. 2012; 86: 9583-9589. doi: 10.1128/JVI.00996-12 PMID: 22761379
71. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med. 2009; 15: 293-299. doi: 10.1038/nm.1935 PMID: 19219024
72. Ndhlovu ZM, Proudfoot J, Cesa K, Alvino DM, McMullen A, Vine S, et al. Elite controllers with low to absent effector CD8+ T cell responses maintain highly functional, broadly directed central memory responses. J Virol. 2012; 86: 6959-6969. doi: 10.1128/JVI.00531-12 PMID: 22514340
73. Kaufman DR, Bivas-Benita M, Simmons NL, Miller D, Barouch DH. Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes. J Virol. 2010; 84: 5986-5996. doi: 10.1128/JVI.02563-09 PMID: 20357087
74. Masek-Hammerman K, Li H, Liu J, Abbink P, La Porte A, O'Brien KL, et al. Mucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5. J Virol. 2010; 84: 9810-9816. doi: 10.1128/JVI.01157-10 PMID: 20686023
75. Belyakov IM, Hel Z, Kelsall B, Kuznetsov VA, Ahlers JD, Nacsa J, et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med. 2001; 7: 1320-1326. PMID: 11726972
76. Genescà M, McChesney MB, Miller CJ. Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6. J Intern Med. 2009; 265: 67-77. doi: 10.1111/j.1365-2796.2008.02051.x PMID: 19093961
77. Genescà M, Skinner PJ, Hong JJ, Li J, Lu D, McChesney MB, et al. With minimal systemic T-cell expansion, CD8+ T Cells mediate protection of rhesus macaques immunized with attenuated simian-human immunodeficiency virus SHIV89.6 from vaginal challenge with simian immunodeficiency virus. J Virol. 2008; 82: 11181-11196. doi: 10.1128/JVI.01433-08 PMID: 18787003
78. Schultheiss T, Schulte R, Sauermann U, Ibing W, Stahl-Hennig C. Strong mucosal immune responses in SIV infected macaques contribute to viral control and preserved CD4+ T-cell levels in blood and mucosal tissues. Retrovirology. 2011; 8: 24. doi: 10.1186/1742-4690-8-24 PMID: 21481223
79. Critchfield JW, Young DH, Hayes TL, Braun JV, Garcia JC, Pollard RB, et al. Magnitude and complexity of rectal mucosa HIV-1-specific CD8+ T-cell responses during chronic infection reflect clinical status. PLoS One. 2008; 3: e3577. doi: 10.1371/journal.pone.0003577 PMID: 18974782
80. Ferre AL, Hunt PW, Critchfield JW, Young DH, Morris MM, Garcia JC, et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood. 2009; 113: 3978-3989. doi: 10.1182/blood-2008-10-182709 PMID: 19109229
81. Sankaran S, Guadalupe M, Reay E, George MD, Flamm J, Prindiville T, et al. Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors. Proc Natl Acad Sci U S A. 2005; 102: 9860-9865. PMID: 15980151
82. Kaul R, Plummer FA, Kimani J, Dong T, Kiama P, Rostron T, et al. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol. 2000; 164: 1602-1611. PMID: 10640781
83. Peiperl L, Morgan C, Moodie Z, Li H, Russell N, Graham BS, et al. Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054). PLoS One. 2010; 5: e13579. doi: 10.1371/journal.pone.0013579 PMID: 21048953
84. Keefer MC, Gilmour J, Hayes P, Gill D, Kopycinski J, Cheeseman H, et al. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012; 7: e41936. doi: 10.1371/journal.pone.0041936 PMID: 22870265
85. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012; 366: 1275-1286. doi: 10.1056/NEJMoa1113425 PMID: 22475592
86. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009; 361: 2209-2220. doi: 10.1056/NEJMoa0908492 PMID: 19843557